11 patients with stage III or IV 6 had response of prolonged SD SD time is 5.5 to 11.1 months 1 had a 20% regression of tumor Patents with SD had improved quality of life No dose-limiting toxicities found No drug-related toxicity greater than grade II
65 patients with stage II or III Tumor RR for combination and TACE alone were 40% and 25% AFP RR for combination and TACE alone were 73.1% and 0.7% TTP for combination and TACE alone were 7.0 and 5.5 months Improved immune function evaluated by CD3+, CD4+, and CD4+/CD8+ Improved QoL Reduced TACE-induced adverse reaction of liver damage
18 advanced liver cancer patients were enrolled in phase I study to determine a safe and tolerable dose 39 advanced liver cancer patients were enrolled in phase II study to observe tumor response, OS, TTP, and QoL No patient experienced drug-related grade 4 or 5 toxicities Disease control rate was 65.2% : 8.7% MR and 56.5% SD OS was 9.2 months TTP was 3.4 months The 12-month survival rate was 44.5% OS for HBV/HCV and non-HBV/HCV subgroups were 13.8 and 7.6 months OS for Child-Pugh A and Child-Pugh B patients were 10.9 and 6.5 months OS for Asian and non-Asian subgroups were 16.5 and 6.2 months Patients’ QoL did not deteriorate significantly and changes in score did not exceed 25%
Gekko japonicas Dumeril et Bibron, Bungarus Parvus, Agkistrodon, etc.
Anticancer
98 liver cancer patients RR (CR + PR) was 60.38% when combined with TACE, while TACE alone was 40.00% KPS scores were higher than TACE alone No adverse reaction Jinlong capsule found Level of serum OPN was lower than that of TACE alone
TACE: transcatheter arterial chemoembolization; OS: overall survival; TTP: time to disease progression; QoL: quality of life; SD: stable disease; CR: complete response; PR: partial response; RR = CR + PR: total response rate.
